Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
$0.30
-1.8%
$0.28
$0.22
$3.67
$11.87M3.031.59 million shs138,462 shs
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.18
-0.9%
$2.24
$1.63
$4.66
$11.29M0.82263,464 shs12,792 shs
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$0.35
+0.5%
$0.42
$0.31
$3.89
$10.97M1.07897,956 shs359,676 shs
NSTGQ
NanoString Technologies
$0.07
$0.07
$0.04
$5.18
$3.45M0.199.78 million shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
0.00%-15.56%+8.92%-9.33%-88.31%
BioCardia, Inc. stock logo
BCDA
BioCardia
0.00%+0.46%-6.03%-16.15%-39.94%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
0.00%-3.09%-16.87%-59.41%+34,499,900.00%
NSTGQ
NanoString Technologies
0.00%0.00%0.00%0.00%-11.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
2.7066 of 5 stars
3.03.00.00.02.22.51.3
BioCardia, Inc. stock logo
BCDA
BioCardia
3.6989 of 5 stars
3.85.00.00.03.02.50.6
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
1.497 of 5 stars
3.53.00.00.00.00.00.6
NSTGQ
NanoString Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
2.00
Hold$13.834,450.44% Upside
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.001,046.79% Upside
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3.00
Buy$10.002,798.55% Upside
NSTGQ
NanoString Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/A$3.42 per shareN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
$3K3,762.68N/AN/A($1.11) per share-1.96
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$50K219.37N/AN/A($2.32) per share-0.15
NSTGQ
NanoString Technologies
$127.26M0.03N/AN/A$0.98 per share0.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$117.67M-$2.07N/AN/AN/AN/A-115.62%-88.94%7/30/2025 (Estimated)
BioCardia, Inc. stock logo
BCDA
BioCardia
-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%8/12/2025 (Estimated)
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/A
NSTGQ
NanoString Technologies
-$159.54M-$3.53N/AN/A-102.44%N/A-53.79%N/A

Latest NSTGQ, ATHA, BCDA, and CLDI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.39-$0.59-$0.20-$0.59N/AN/A
5/9/2025Q1 2025
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$0.20-$0.23-$0.03-$0.23N/AN/A
3/26/2025Q4 2024
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/AN/A
NSTGQ
NanoString Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/A
2.95
2.95
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
1.78
1.78
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/A
0.19
0.19
NSTGQ
NanoString Technologies
N/A
2.73
2.02

Institutional Ownership

CompanyInstitutional Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
57.12%
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
12.53%
NSTGQ
NanoString Technologies
76.77%

Insider Ownership

CompanyInsider Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
22.10%
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
6.70%
NSTGQ
NanoString Technologies
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
4039.04 million31.01 millionOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
405.18 million3.67 millionOptionable
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3831.79 million20.04 millionN/A
NSTGQ
NanoString Technologies
55048.12 million46.63 millionOptionable

Recent News About These Companies

NanoString Technologies, Inc. (NSTGQ)
NanoString Technologies Inc (NSTGQ)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Athira Pharma stock logo

Athira Pharma NASDAQ:ATHA

$0.30 -0.01 (-1.78%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$0.31 +0.01 (+1.64%)
As of 06/13/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.17 -0.03 (-1.36%)
As of 06/13/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Calidi Biotherapeutics stock logo

Calidi Biotherapeutics NYSE:CLDI

$0.34 +0.00 (+0.47%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$0.33 -0.01 (-3.77%)
As of 06/13/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

NanoString Technologies NASDAQ:NSTGQ

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.